1-4 of 4
arabinofuranosyluracil
Close
Sort by
Journal Articles

Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction

Mina Nikanjam, MD PhD, Edmund Capparelli, PharmD, Jeffrey E. Lancet, MD, Jonathan E. Kolitz, MD, Arthur C. Louie, MD, Gary J. Schiller, MD
Journal: Blood
Blood (2016) 128 (22): 3955.
https://doi.org/10.1182/blood.V128.22.3955.3955
Published: 2016
Journal Articles

CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia

Tara L. Lin, MD, Laura F. Newell, MD, Robert K. Stuart, MD, Laura C. Michaelis, MD, Stephen E. Rubenstein, MD, Helen S. Pentikis, PhD, Timothy Callahan, PhD, Donna Alvarez, Lawrence D. Mayer, PhD, Arthur C. Louie, MD
Journal: Blood
Blood (2015) 126 (23): 2510.
https://doi.org/10.1182/blood.V126.23.2510.2510
Published: 2015
Journal Articles

Novel Population Pharmacokinetic Modeling of Arabinosyl Cytosine Triphosphate: Insights On Potential Preferential Formation of Ara-CTP Directly From Elacytarabine As Well As From Ara-C

Corinne Seng Yue, Varsha V. Gandhi, Ph.D., Susan O'Brien, M.D., Farhad Ravandi, MD, Tove Flem Jacobsen, Hubert Dirven, PhD, Steinar Hagen, PhD, Petter-Arnt Hals, PhD, Murray Ducharme, PhD
Journal: Blood
Blood (2012) 120 (21): 3547.
https://doi.org/10.1182/blood.V120.21.3547.3547
Published: 2012
Journal Articles

Overexpression of GATA1 Confers Chemotherapy Resistance in Pediatric Acute Megakaryocytic Leukemia.

Holly Edwards, Chengzhi Xie, Alan Dombkowski, Maggie Keller, Mark Stout, Steven Buck, Larry Matherly, PhD, Jeffrey Taub, MD, Yubin Ge, PhD
Journal: Blood
Blood (2009) 114 (22): 2039.
https://doi.org/10.1182/blood.V114.22.2039.2039
Published: 2009